PULSE CYCLOPHOSPHAMIDE FOLLOWED BY TREATMENT W/ITH AVONEX

$0M01FY2002RRNIH

Brigham And Women'S Hospital, Boston MA

Investigators

Linked publications & trials

Paper 38932724 Paper 38114500 Paper 37996284 Paper 37748973 Paper 36376588 Paper 35436355 Paper 35115537 Paper 34493686 Paper 34402783 Paper 34061954 Paper 34045018 Paper 33774680 Paper 33615722 Paper 33051649 Paper 32966825 Paper 32423348 Paper 32364602 Paper 31723161 Paper 31672933 Paper 31670824 Paper 31593837 Paper 31446439 Paper 31415086 Paper 31206400 Paper 30862011 Paper 30737489 Paper 30722039 Paper 30690866 Paper 30682628 Paper 30557062 Paper 29946297 Paper 29884610 Paper 29784810 Paper 29707782 Paper 29684473 Paper 29622171 Paper 29384243 Paper 29212952 Paper 29141784 Paper 28993451 Paper 28985281 Paper 28874358 Paper 28790874 Paper 28744601 Paper 28694840 Paper 28618170 Paper 28566337 Paper 28516162 Paper 28490834 Paper 28411157 Paper 28405608 Paper 28403049 Paper 28361235 Paper 28340516 Paper 28323995 Paper 28216802 Paper 28138133 Paper 27836939 Paper 27836938 Paper 27523583 Paper 27466884 Paper 27019198 Paper 26868293 Paper 26737854 Paper 26733571 Paper 26632430 Paper 26505746 Paper 26380159 Paper 26373701 Paper 26245315 Paper 26071654 Paper 26043207 Paper 25959971 Paper 25946480 Paper 25935025 Paper 25926410 Paper 25825948 Paper 25773686 Paper 25759571 Paper 25640603 Paper 25548261 Paper 25506933 Paper 25452149 Paper 25184442 Paper 25029420 Paper 24966274 Paper 24878041 Paper 24664291 Paper 24501435 Paper 24489656 Paper 24423322 Paper 24423319 Paper 24336419 Paper 24335056 Paper 24332222 Paper 24226101 Paper 24191286 Paper 24179309 Paper 24144899 Paper 24136332

Abstract

This is a randomized trial of two standard approaches to therapy of patients with multiple sclerosis remaining active despite therapy with beta-interferons. One arm receives cytoxan plus solumedrol plus continued beta-interferons, while the other receives only solumedrol plus beta-interferons. There will be 20 patients at BWH and 20 at MGH, stratified for disease severity assessed by number of gadolinium lesions. This is an investigator-initiated, industry sponsored clinical trial.

View original record on NIH RePORTER →